miR‐101 targets enhancer of zeste homolog 2 (EZH2), a marker for aggressive breast cancer (Kleer et al., 2003), and an upregulation of miR‐101 results in decreased EZH2 levels. This evidence concerns the gene EZH2 and breast carcinoma.